(Q34287101)

1 August 2017

Combinatorial drug therapy for cancer in the post-genomic era. (English)

1 reference

1 August 2017

Bissan Al-Lazikani

1

0 references

Udai Banerji

object named as

Udai Banerji

series ordinal

2

0 references

Paul Workman

series ordinal

3

object named as

Paul Workman

1 reference

PubMed ID

22781697

1 August 2017

language of work or name

1 reference

10 July 2012

1 reference

1 August 2017

1 reference

1 August 2017

30

1 reference

1 August 2017

679-692

1 reference

1 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt.2284

1 August 2017

0 references

cites work

Life in the fast lane: mammalian disease models in the genomics era.

1 reference

12 December 2020

Reactome: a database of reactions, pathways and biological processes

1 reference

12 December 2020

Systems biology and new technologies enable predictive and preventative medicine.

1 reference

12 December 2020

Development of therapeutic combinations targeting major cancer signaling pathways

1 reference

12 December 2020

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

12 December 2020

Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

1 reference

12 December 2020

Adaptive clinical trials in oncology

1 reference

12 December 2020

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

12 December 2020

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

1 reference

12 December 2020

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

12 December 2020

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

1 reference

12 December 2020

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

1 reference

12 December 2020

Spatio-temporal correlations can drastically change the response of a MAPK pathway

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Development of novel combination therapies

1 reference

12 December 2020

Chemical combination effects predict connectivity in biological systems

1 reference

12 December 2020

Circumventing cancer drug resistance in the era of personalized medicine

1 reference

12 December 2020

Modeling of protein signaling networks in clinical proteomics

1 reference

12 December 2020

Discovery of small molecule cancer drugs: successes, challenges and opportunities

1 reference

12 December 2020

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

1 reference

12 December 2020

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

12 December 2020

The expected effect of a combination of agents: the general solution.

1 reference

12 December 2020

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

1 reference

12 December 2020

Next-generation genomics: an integrative approach

1 reference

12 December 2020

Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics

1 reference

12 December 2020

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

1 reference

12 December 2020

A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Tumour evolution inferred by single-cell sequencing

1 reference

12 December 2020

Mechanisms of cancer drug resistance

1 reference

12 December 2020

Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

1 reference

12 December 2020

Timeline: Chemotherapy and the war on cancer.

1 reference

12 December 2020

Personalized medicine: patient-predictive panel power

1 reference

12 December 2020

Chemogenomic profiling: identifying the functional interactions of small molecules in yeast

1 reference

12 December 2020

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

12 December 2020

Heat shock protein 90 as a drug target: some like it hot.

1 reference

12 December 2020

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

12 December 2020

Multicomponent therapeutics for networked systems

1 reference

12 December 2020

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl

1 reference

12 December 2020

Clonal evolution in cancer

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks

1 reference

12 December 2020

The genetic landscape of a cell

1 reference

12 December 2020

Pathway Commons, a web resource for biological pathway data

1 reference

12 December 2020

Guidelines for the welfare and use of animals in cancer research

1 reference

12 December 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Gene amplification and drug resistance in cultured murine cells.

1 reference

12 December 2020

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

1 reference

12 December 2020

Epigenetic biomarkers for human cancer: the time is now.

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

12 December 2020

Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy

1 reference

12 December 2020

Kinetic simulation of anticancer drug interactions

1 reference

12 December 2020

Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database

1 reference

12 December 2020

ROCK: a breast cancer functional genomics resource.

1 reference

12 December 2020

From an ethics of rationing to an ethics of waste avoidance

1 reference

12 December 2020

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors

1 reference

12 December 2020

The Database of Interacting Proteins: 2004 update

1 reference

12 December 2020

A human phenome-interactome network of protein complexes implicated in genetic disorders

1 reference

12 December 2020

Hallmarks of Cancer: The Next Generation

1 reference

12 December 2020

Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli

1 reference

12 December 2020

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

12 December 2020

Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis

1 reference

12 December 2020

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

A global analysis of cross-talk in a mammalian cellular signalling network

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Combining targeted therapies: practical issues to consider at the bench and bedside

1 reference

12 December 2020

Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing

1 reference

12 December 2020

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

1 reference

12 December 2020

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

1 reference

12 December 2020

Intratumor heterogeneity: seeing the wood for the trees.

1 reference

12 December 2020

Causal protein-signaling networks derived from multiparameter single-cell data

1 reference

12 December 2020

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

1 reference

12 December 2020

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

1 reference

12 December 2020

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

1 reference

12 December 2020

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

12 December 2020

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

1 reference

12 December 2020

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

1 reference

12 December 2020

PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation

1 reference

12 December 2020

Genetic variegation of clonal architecture and propagating cells in leukaemia

1 reference

12 December 2020

Personal omics profiling reveals dynamic molecular and medical phenotypes

1 reference

12 December 2020

Open access chemical and clinical probes to support drug discovery

1 reference

12 December 2020

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

1 reference

12 December 2020

Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells

1 reference

12 December 2020

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

1 reference

12 December 2020

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer therapy

1 reference

12 December 2020

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

Hsp90 molecular chaperone inhibitors: are we there yet?

1 reference

12 December 2020

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

1 reference

12 December 2020

Clinical implications of the cancer genome

1 reference

12 December 2020

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

12 December 2020

MINT, the molecular interaction database: 2009 update

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities

1 reference

12 December 2020

Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?

1 reference

12 December 2020

Envisioning the future of early anticancer drug development.

1 reference

12 December 2020

Utilizing RNA interference to enhance cancer drug discovery

1 reference

12 December 2020

Combination chemical genetics

1 reference

12 December 2020

Abiraterone and increased survival in metastatic prostate cancer

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS.

1 reference

12 December 2020

Enzyme kinetics and combination chemotherapy: An appraisal of current concepts

1 reference

12 December 2020

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

12 December 2020

Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency

1 reference

12 December 2020

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

1 reference

12 December 2020

BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models

1 reference

12 December 2020

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

12 December 2020

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

12 December 2020

Evolution of resistance to anti-cancer therapy during general dosing schedules

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Anticancer therapy with checkpoint inhibitors: what, where and when?

1 reference

12 December 2020

Prediction of drug combinations by integrating molecular and pharmacological data

1 reference

12 December 2020

Translating cancer research into targeted therapeutics

1 reference

12 December 2020

Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer

1 reference

12 December 2020

A blueprint for advancing genetics-based cancer therapy

1 reference

12 December 2020

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

12 December 2020

CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models

1 reference

12 December 2020

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

1 reference

12 December 2020

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

1 reference

12 December 2020

The IntAct molecular interaction database in 2010

1 reference

12 December 2020

canSAR: an integrated cancer public translational research and drug discovery resource

1 reference

12 December 2020

1 reference

12 December 2020

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

12 December 2020

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

1 reference

12 December 2020

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

1 reference

12 December 2020

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

The Hsp90 molecular chaperone: an open and shut case for treatment

1 reference

12 December 2020

Cancer models, genomic instability and somatic cellular Darwinian evolution

1 reference

12 December 2020

Comparing signaling networks between normal and transformed hepatocytes using discrete logical models

1 reference

12 December 2020

Believe it or not: how much can we rely on published data on potential drug targets?

1 reference

12 December 2020

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Predicting selective drug targets in cancer through metabolic networks.

1 reference

12 December 2020

Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes

1 reference

12 December 2020

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

12 December 2020

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

12 December 2020

The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action

1 reference

12 December 2020

The BioGRID Interaction Database: 2011 update

1 reference

12 December 2020

Reactome pathway analysis to enrich biological discovery in proteomics data sets

1 reference

12 December 2020

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

12 December 2020

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

12 December 2020

Computational modeling of mammalian signaling networks

1 reference

12 December 2020

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

1 reference

12 December 2020

Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor

1 reference

12 December 2020

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

1 reference

12 December 2020

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

12 December 2020

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

1 reference

12 December 2020

A census of human cancer genes

1 reference

12 December 2020

The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored

1 reference

12 December 2020

Identifiers

DOI

10.1038/NBT.2284

1 reference

PubMed ID

22781697

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

22781697